Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
359 Leser
Artikel bewerten:
(1)

TFS Forms Partnership to Conduct a Global RWE Study on Covid-19 Pandemic

STOCKHOLM, April 1, 2020 /PRNewswire/ -- TFS joins Observational Health Data Sciences and Informatics (OHDSI) community in a COVID-19 virtual study-a-thon (March 26-29) to inform healthcare decision-making in response to the current global pandemic. With the increasing availability of real-world COVID-19 data worldwide the main purpose of the event is to generate immediate real-world evidence on prioritized questions shared by national governments, public health agencies, health-related institutions, and community members; and to design COVID-19-specific studies that can be validated and available to run when such data is available. (source: ohdsi.org)

TFS partners with IOMED on a recently approved local RWE study, "COVID-19 REAL". Within this strategicpartnership, TFS will analyze data using the standardized tools provided by the OHDSI collaboration. TheCOVID-19 REAL focuses on helping address current gaps in the management of COVID-19 pandemic. It isa non-interventional, retrospective, database, cohort study based on anonymized and routinelycollectedhealth care data from several Spanish Hospitals. All generated real-world evidence will beplaced in the public domain to support and inform current public health efforts. Patient privacy will beprotected in all studies.

Coronavirus disease 2019 (COVID-19) pandemic has an urgent need for answering many questions regarding epidemiology and natural history of the disease. Neus Valveny, TFS Operational Strategy Lead Real World Evidence, addresses the importance of real world evidence to complement clinical trial results. "Similarities and differences with other viral infections as well as effectiveness and safety of current preventive or therapeutic measures are extremely important. Models assessing most relevant prognostic factors in the daily practice will be also crucial to help healthcare providers decide which subjects should be prioritized and given more intensive therapies. The full analysis needs to be adjusted for potential confounding and biases inherent to observational research."

For further information, please contact:

Sylwia Domagalska
Director Marketing and Corporate Communications
Email: sylwia.domagalska@tfscro.com
Phone: +48-787-913-074

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/tfs/r/tfs-forms-partnership-to-conduct-a-global-rwe-study-on-covid-19-pandemic-,c3078702

The following files are available for download:

https://news.cision.com/tfs/i/coronavirus-2,c2768213

Coronavirus 2

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.